跳转至内容
Merck

M1750000

甲基强的松龙

European Pharmacopoeia (EP) Reference Standard

别名:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H30O5
CAS号:
分子量:
374.47
Beilstein:
2340300
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

methylprednisolone

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

運輸包裝

wet ice

SMILES 字串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI 密鑰

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因資訊

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Methylprednisolone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 2

標靶器官

Adrenal gland,Immune system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

MMWR. Morbidity and mortality weekly report, 62(19), 377-381 (2013-05-17)
As of May 6, 2013, Michigan had reported 167 (52%) of the 320 paraspinal or spinal infections without meningitis associated with the 2012-2013 fungal meningitis outbreak nationally. Although the index patient had a laboratory-confirmed Aspergillus fumigatus infection, the fungus most
Juho Keski-Nisula et al.
The Annals of thoracic surgery, 95(6), 2126-2132 (2013-04-23)
Corticosteroids are widely used in pediatric open-heart surgery to reduce systemic inflammatory response and to mediate possible cardioprotective effects. However, the optimal dosing of corticosteroids is unknown and their administration varies considerably between different institutions. Forty neonates undergoing open-heart surgery
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to
Robert J Fox et al.
Neurology, 82(17), 1491-1498 (2014-04-01)
RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients
Tyree H Kiser et al.
American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)
Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门